Capital Research Global Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.35B | Buy |
7,191,656
+36,928
| +0.5% | +$12M | 0.47% | 50 |
|
|
2025
Q1 | $1.93B | Buy |
7,154,728
+186,215
| +3% | +$50.3M | 0.42% | 60 |
|
|
2024
Q4 | $1.64B | Buy |
6,968,513
+1,724,610
| +33% | +$406M | 0.34% | 67 |
|
|
2024
Q3 | $1.44B | Buy |
5,243,903
+1,988,255
| +61% | +$547M | 0.3% | 75 |
|
|
2024
Q2 | $791M | Buy |
3,255,648
+110,661
| +4% | +$26.9M | 0.17% | 112 |
|
|
2024
Q1 | $470M | Buy |
3,144,987
+214,908
| +7% | +$32.1M | 0.11% | 151 |
|
|
2023
Q4 | $561M | Buy |
2,930,079
+146,236
| +5% | +$28M | 0.14% | 144 |
|
|
2023
Q3 | $493M | Buy |
2,783,843
+429,082
| +18% | +$76M | 0.14% | 149 |
|
|
2023
Q2 | $447M | Sell |
2,354,761
-84,835
| -3% | -$16.1M | 0.12% | 153 |
|
|
2023
Q1 | $489M | Buy |
2,439,596
+1,607,479
| +193% | +$322M | 0.14% | 136 |
|
|
2022
Q4 | $198M | Buy |
+832,117
| New | +$198M | 0.06% | 215 |
|